|Company name||Amneal Pharmaceuticuals, Inc.|
NEW YORK, June 26, 2019 – Bragar Eagel & Squire, P.C. is investigating potential claims against Amneal Pharmaceuticals (NYSE: AMRX) on behalf of Amneal stockholders. Our investigation concerns whether Amneal has violated the federal securities laws and/or engaged in other unlawful business practices.
For many years, the Company, (formerly Impax Laboratories Inc.), which develops, manufactures, and markets bioequivalent, generic, pharmaceutical products, has been embroiled in investigations and litigation by state and federal authorities relating to claims that it colluded with other competitor companies in a price-fixing scheme resulting in exponential price increases of certain products. Recently, the Company was among those sued in a wide-ranging lawsuit brought by 44 state attorneys general alleging an illegal conspiracy to inflate prices of more than 100 generic drugs, sometimes by more than 1,000%, and stifle competition.
If you purchased or otherwise acquired Amneal shares and have suffered a loss, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at firstname.lastname@example.org, or telephone at (212) 355-4648, or by filling out the contact form below. There is no cost or obligation to you.